Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
ALLOCORD, HPC (Hematopoietic Progenitor Cell) Cord Blood, is an allogeneic cord blood hematopoietic progenitor cell therapy indicated for use in unrelated-donor hematopoietic progenitor stem cell transplantation procedures. The therapy is delivered in conjunction with an appropriate preparative regimen for hematopoietic and immunologic reconstitution in patients with disorders affecting the hematopoietic system that are inherited, acquired, or result from myeloablative treatment.
Matching for at least 4 of 6 HLA-A antigens, HLA-B antigens, and HLA-DRB1 alleles is recommended.
Treatment led to 88% neutrophil recovery by day 42 and platelet recovery by day 100.
Read More
Contraindications: Known sensitivity to dimethyl sulfoxide (DMSO), Dextran 40 or plasma proteins.
Fatal infusion reactions: ALLOCORD administration can result in serious, including fatal, infusion reactions.
Graft-vs.-host disease (GVHD): GVHD is expected after administration of ALLOCORD, and may be fatal. Administration of immunosuppressive therapy may decrease the risk of GVHD.
Engraftment syndrome: Engraftment syndrome may progress to multi-organ failure and death. Treat engraftment syndrome promptly with corticosteroids.
Graft failure: Graft failure may be fatal.
Read More
Product Information for
Allocord, cord blood-derived hematopoietic progenitor cells for hematopoietic reconstitution
Links related to the product - may include a range of information sources (e.g., press releases, websites, patents) related to the specific cell therapy application.
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access
Access to this data is limited to
LifeMap Discovery Registered users onlySign in for full access